

Xantos Biomedicine AG Successfully Advances a Development Project for Roche

Munich, Germany, January 21st 2005 - Xantos Biomedicine AG, a leading functional biology and drug discovery company, announced that it has successfully completed a drug profiling project for Roche Pharma Research Penzberg. The results significantly supported Roche's further research activities in this program.

Xantos employed its proprietary High Throughput Cellular Screening Technology, XantoScreen™ and the Company's full-length human clone collection, which comprises 35,000 cDNA clones, to help pinpoint the molecular target and pathway for a novel potent anti-tumour compound. As part of the study Xantos implemented and customised a cell based assay for measuring compound effects by functional profiling.

Dr. Hans-Joachim Mueller, Roche, commented, "The outcome of the project went well beyond our initial expectations. Xantos' results are helping us to identify the molecular mode of action of our anti-cancer compound. The process also identified human proteins that could modulate the effect of our compound and thereby helped us to understand pharmacological effects in preclinical studies. We very much enjoyed working with the Xantos team and look forward to working with them again in the near future."

Dr. Ulrich Brinkmann, CSO of Xantos, commented, "I am delighted that we successfully applied our technology to support Roche in their attempts to find better cancer drugs. This achievement further endorses the application of our technology in drug discovery and development."

About Xantos Biomedicine AG - www.xantos.de

Xantos Biomedicine AG is a functional biology and drug discovery company that is focusing on the identification and validation of disease relevant human genes. Studies on biological functions are carried out rapidly by screening for phenotypic changes caused by increase of gene function in mammalian cell systems. For this Xantos has established the proprietary high-throughput, fully automated cellular gene-transfection and assay system **XantoScreen™** that is used for several functional applications:

- Molecular drug profiling
- Target / pathway profiling
- Target and protein identification and
- Lead identification

XantoScreen™ enables the fully automated and standardized functional analysis of 100,000 to 300,000 genes per month in cell systems. Xantos has one of the world's largest full-length human cDNA collections (35,000 clones), several high quality cDNA libraries from various human tissues and several cell systems available for high throughput analysis. The Company uses its

technology for its own discovery programs in cancer and metabolic diseases.

Xantos focuses on the development of therapeutics based on secreted proteins involved in angiogenesis of cancer cells, in differentiation of fat cells and in the induction of insulin resistance. Xantos has already identified several disease relevant new targets and proteins and is searching for collaboration partners. Xantos is offering its technology, the human cDNA collections, libraries and functional cell assay systems on a fee-for-service basis for technology-driven interactions.

For further information about the company please contact:

Angelika Bonin-Debs
Xantos Biomedicine AG
Max- Lebsche-Platz 31
D-81377 Munich,
Germany
Tel: +49 89 899 59 509
Fax: +49 89 899 59 420
E- mail: [a.bonin- debs@xantos.de](mailto:a.bonin-debs@xantos.de)

International/English language media enquiries:

Dr Eileen Paul
Northbank Communications
Tel: +44 (0) 1260 296500
Mobile: +44 (0) 7793630240
E.mail: e.paul@northbankcommunications.com

German media enquiries:

Marc Egelhofer
Northbank Communications
Tel: +44 (0) 1260 296500
Mobile: +49 (0) 1788726392
E-mail: m.egelhofer@northbankcommunications.com